Phase 1 × Recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Clear all Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Phase 1 Recruiting
54 enrolled
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Phase 1 Recruiting
10 enrolled
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
Phase 1 Recruiting
29 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Phase 1 Recruiting
48 enrolled
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Phase 1 Recruiting
7 enrolled
REALIZE
Phase 1 Recruiting
60 enrolled
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Phase 1 Recruiting
27 enrolled
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Phase 1 Recruiting
30 enrolled
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 Recruiting
20 enrolled
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Phase 1 Recruiting
30 enrolled
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1 Recruiting
300 enrolled
PRODIGY
Phase 1 Recruiting
10 enrolled
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 Recruiting
18 enrolled
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 Recruiting
20 enrolled
INVISE
Phase 1 Recruiting
34 enrolled
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 Recruiting
24 enrolled
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Phase 1 Recruiting
18 enrolled
CD19 CART CELL
Phase 1 Recruiting
24 enrolled
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Phase 1 Recruiting
15 enrolled
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Phase 1 Recruiting
50 enrolled
SAGAN
Phase 1 Recruiting
64 enrolled
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Phase 1 Recruiting
24 enrolled
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Phase 1 Recruiting
60 enrolled
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Phase 1 Recruiting
24 enrolled
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
Phase 1 Recruiting
10 enrolled
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Phase 1 Recruiting
33 enrolled
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 Recruiting
242 enrolled
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Phase 1 Recruiting
22 enrolled
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 Recruiting
44 enrolled
REALL_CART
Phase 1 Recruiting
10 enrolled
A Phase I Dose Finding Study of MB-CART2219.1
Phase 1 Recruiting
36 enrolled
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
Phase 1 Recruiting
12 enrolled
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 Recruiting
65 enrolled
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Phase 1 Recruiting
54 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Recruiting
36 enrolled
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Phase 1 Recruiting
50 enrolled
TCCA
Phase 1 Recruiting
28 enrolled
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Phase 1 Recruiting
22 enrolled
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 Recruiting
10 enrolled
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 Recruiting
54 enrolled
CARLA
Phase 1 Recruiting
6 enrolled
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Phase 1 Recruiting
48 enrolled
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1 Recruiting
100 enrolled
VICTORY
Phase 1 Recruiting
18 enrolled
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
Phase 1 Recruiting
20 enrolled
ALaCART
Phase 1 Recruiting
40 enrolled